AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for AVEO
1.32
+0.03 (2.33%)
Aug 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.26 - 1.33
52 week 1.00 - 2.36
Open 1.30
Vol / Avg. 356,855.00/463,967.00
Mkt cap 69.03M
P/E     -
Div/yield     -
EPS -1.27
Shares 52.30M
Beta 1.01
Inst. own 48%
Nov 3, 2014
Q3 2014 Aveo Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Aug 11, 2014
Q2 2014 AVEO Oncology Earnings Release
Jun 19, 2014
AVEO Oncology Annual Shareholder Meeting
Jun 5, 2014
AVEO Oncology at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -972.86% -8277.57%
Operating margin -946.10% -8035.89%
EBITD margin - -7121.96%
Return on average assets -62.08% -60.50%
Return on average equity -129.53% -113.33%
Employees 71 -
CDP Score - -

Address

650 E. KENDALL STREET
CAMBRIDGE, MA 02142
United States - Map
+1-617-2995000 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, is a biopharmaceutical company. The Company is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase II trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors, and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite.

Officers and directors

Henri A. Termeer Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Tuan Ha-Ngoc President, Chief Executive Officer, Principal Financial Officer, Director
Age: 62
Bio & Compensation  - Reuters
Joseph Vittiglio Senior Vice President, General Counsel
Age: 42
Bio & Compensation  - Reuters
Jeno Gyuris Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Michael P. Bailey Chief Business Officer
Age: 48
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 63
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Raju S. Kucherlapati Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Robert C. Young M.D Independent Director
Age: 74
Bio & Compensation  - Reuters